CL2016001023A1 - Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2. - Google Patents

Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2.

Info

Publication number
CL2016001023A1
CL2016001023A1 CL2016001023A CL2016001023A CL2016001023A1 CL 2016001023 A1 CL2016001023 A1 CL 2016001023A1 CL 2016001023 A CL2016001023 A CL 2016001023A CL 2016001023 A CL2016001023 A CL 2016001023A CL 2016001023 A1 CL2016001023 A1 CL 2016001023A1
Authority
CL
Chile
Prior art keywords
dimethylpyrimidin
oxopropan
cyclopropanecarboxamide
ghrelin
acyltransferase
Prior art date
Application number
CL2016001023A
Other languages
English (en)
Inventor
Grau Maria Angeles Martinez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2016001023A1 publication Critical patent/CL2016001023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuesto N-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, su enantiómero, inhibidor de grelina o-aciltransferasa (GOAT); composición farmacéutica y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2
CL2016001023A 2013-11-14 2016-04-29 Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2. CL2016001023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382460 2013-11-14

Publications (1)

Publication Number Publication Date
CL2016001023A1 true CL2016001023A1 (es) 2016-11-18

Family

ID=49622771

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001023A CL2016001023A1 (es) 2013-11-14 2016-04-29 Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2.

Country Status (39)

Country Link
US (1) US9035051B1 (es)
EP (1) EP3068775B1 (es)
JP (1) JP6159484B2 (es)
KR (1) KR101739243B1 (es)
CN (1) CN105636948B (es)
AP (1) AP2016009189A0 (es)
AR (1) AR098274A1 (es)
AU (1) AU2014348967B2 (es)
BR (1) BR112016009488B1 (es)
CA (1) CA2926224C (es)
CL (1) CL2016001023A1 (es)
CR (1) CR20160184A (es)
CY (1) CY1119489T1 (es)
DK (1) DK3068775T3 (es)
DO (1) DOP2016000070A (es)
EA (1) EA028550B1 (es)
ES (1) ES2647790T3 (es)
HR (1) HRP20171648T1 (es)
HU (1) HUE035590T2 (es)
IL (1) IL244856A (es)
JO (1) JO3302B1 (es)
LT (1) LT3068775T (es)
MA (1) MA39025B1 (es)
ME (1) ME02841B (es)
MX (1) MX2016006223A (es)
NO (1) NO3068775T3 (es)
NZ (1) NZ718373A (es)
PE (1) PE20160609A1 (es)
PH (1) PH12016500895A1 (es)
PL (1) PL3068775T3 (es)
PT (1) PT3068775T (es)
RS (1) RS56533B1 (es)
SG (1) SG11201602953YA (es)
SI (1) SI3068775T1 (es)
TN (1) TN2016000145A1 (es)
TW (1) TWI538677B (es)
UA (1) UA118034C2 (es)
WO (1) WO2015073281A1 (es)
ZA (1) ZA201602202B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104672A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AU2017307033B2 (en) * 2016-08-05 2020-11-26 Boehringer Ingelheim International Gmbh Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
CN106478519B (zh) * 2016-10-10 2018-12-11 上海再启生物技术有限公司 一种2-甲基-4-氨基-6-氯嘧啶的制备方法
MX2020008053A (es) 2018-02-02 2020-09-07 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).
JP7225253B2 (ja) 2018-02-02 2023-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
CN111655699B (zh) 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的杂环基取代的噁二唑并吡啶衍生物
CA3087925A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CN108516971A (zh) * 2018-05-30 2018-09-11 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108558852A (zh) * 2018-05-30 2018-09-21 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
CN108558849A (zh) * 2018-05-30 2018-09-21 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108774221A (zh) * 2018-05-30 2018-11-09 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
CN108610337A (zh) * 2018-05-30 2018-10-02 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
WO2021233884A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403686C (en) * 2000-03-23 2010-01-26 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
US20060233788A1 (en) 2003-09-05 2006-10-19 Heiman Mark L Anti-ghrelin antibodies
US20070237775A1 (en) 2004-07-14 2007-10-11 Eli Lilly And Company Anti-Ghrelin Antibodies
CA2587627A1 (en) 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
US7479271B2 (en) 2005-02-23 2009-01-20 Eli Lilly And Company Humanized anti-ghrelin antibodies
BRPI0610133A2 (pt) * 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
CN101175759A (zh) * 2005-05-17 2008-05-07 先灵公司 作为治疗血脂异常的烟酸受体激动剂的杂环化合物
US20070213359A1 (en) * 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
WO2009117676A2 (en) * 2008-03-20 2009-09-24 Forest Laboratories Holdings Limited Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida

Also Published As

Publication number Publication date
PE20160609A1 (es) 2016-07-03
EP3068775A1 (en) 2016-09-21
AP2016009189A0 (en) 2016-05-31
TWI538677B (zh) 2016-06-21
IL244856A0 (en) 2016-05-31
AR098274A1 (es) 2016-05-18
HUE035590T2 (en) 2018-05-28
ZA201602202B (en) 2019-10-30
EA028550B1 (ru) 2017-11-30
MX2016006223A (es) 2016-08-08
DOP2016000070A (es) 2016-05-30
PL3068775T3 (pl) 2018-01-31
MA39025B1 (fr) 2018-05-31
ME02841B (me) 2018-01-20
KR101739243B1 (ko) 2017-05-23
US9035051B1 (en) 2015-05-19
WO2015073281A1 (en) 2015-05-21
MA39025A1 (fr) 2017-05-31
CY1119489T1 (el) 2018-03-07
DK3068775T3 (en) 2017-10-23
NZ718373A (en) 2017-12-22
JP6159484B2 (ja) 2017-07-05
PH12016500895B1 (en) 2016-06-20
US20150133474A1 (en) 2015-05-14
HRP20171648T1 (hr) 2017-12-15
LT3068775T (lt) 2017-11-27
CR20160184A (es) 2016-06-17
BR112016009488A8 (pt) 2018-01-30
KR20160068926A (ko) 2016-06-15
EP3068775B1 (en) 2017-09-06
CA2926224C (en) 2017-05-02
JO3302B1 (ar) 2018-09-16
SG11201602953YA (en) 2016-05-30
NO3068775T3 (es) 2018-02-03
AU2014348967B2 (en) 2017-05-04
PH12016500895A1 (en) 2016-06-20
CN105636948A (zh) 2016-06-01
TN2016000145A1 (en) 2017-10-06
JP2016537371A (ja) 2016-12-01
BR112016009488B1 (pt) 2021-01-19
RS56533B1 (sr) 2018-02-28
AU2014348967A1 (en) 2016-04-28
SI3068775T1 (sl) 2017-10-30
TW201529073A (zh) 2015-08-01
UA118034C2 (uk) 2018-11-12
EA201690764A1 (ru) 2016-07-29
CN105636948B (zh) 2017-10-24
HK1222860A1 (en) 2017-07-14
PT3068775T (pt) 2017-11-20
CA2926224A1 (en) 2015-05-21
ES2647790T3 (es) 2017-12-26
IL244856A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
CO2018004124A2 (es) Compuestos heterocíclicos
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
CR20150045A (es) Inhibidores de hepatitis c
DK3555070T3 (da) Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
BR112014030473A2 (pt) novo diazaespirocicloalcano e azaespirocicloalcano
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
PE20160838A1 (es) Procedimiento para la preparacion de 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridina-2-carboxamida, sus sales y su monohidrato
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
CL2013000104A1 (es) Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar.
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
MX374541B (es) Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino) pirimidin-4-il)benzamida.
BR112015023399A8 (pt) inibidores de hdac, seu uso e composição farmacêutica
CL2011002442A1 (es) Un compuesto n-(4-(4-(3-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)ureido)naftalen-1-iloxi)piridin-2-il)-2-metoxiacetamida o una sal, estereoisomeros y tautomeros del mismo; composicion farmaceutica; y su uso para tratar o prevenir una afeccion seleccionada de epoc, asma e inhibicion del crecimiento y metastasis de tumores, entre otras.
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
PE20160609A1 (es) Piperidil-etil-pirimidina sustituido como inhibidor de grelina o-acil transferasa
CR11483A (es) Inhibidores de peptido desformilasa
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
CR20140494A (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
CY1123267T1 (el) Κρυσταλλικες μορφες 2-(tpit-boytyλamino)-4-((1r,3r,4r)-3-yδpoξy-4-μεθυλοκυκλοεξυλαμινο)-πυριμιδινο-5-καρβοξαμιδιου
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов